NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in February: Guggenheim Emerging Outlook: Biotech Summit 2026. Fireside chat on Thursday, February 12, 2026 at 12:30 p.m. ET in New York, NY. Oppenheimer 36th Annual Healthcare Life Sciences Conference. Fireside chat ...

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Lexeo Therapeutics, Inc. is placed sixteenth on our list. TheFly reported on January 13 that H.C. Wainwright analyst Mitchell Kapoor lowered the price target for LXEO to $10 from $13 and maintained a Buy rating. The firm believes that the market is still not persuaded by LXEO’s recent PKP2 findings; the drop implies a lesser possibility of acceptance for the PKP2 program. H.C. Wainwright Says Market Remains Unconvinced on Lex ...

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a series of key senior leadership appointments that underscore the company’s continued and growing expertise in cardiovascular medicine and late-stage clinical development. The company also provided an update on the strategic partnership announced in June 2025 with Perceptive Xontogeny Venture Fund ...

PresentationWelcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Tessa Romero, and I'm one of the senior biotech analysts here at JPMorgan. We're pleased to welcome our next presenting company, Lexeo Therapeutics, to kick off our Wednesday. And presenting on behalf of the company, we have CEO, Nolan Townsend. Nolan, over to you.Thank you, Tess. It's great to be here, and thanks, everyone, for coming. We're going to start with a short video to give a flavor of the type of diseases ...

Lexeo Therapeutics (NasdaqGM:LXEO) FY Conference January 14, 2026 10:30 AM ET Company ParticipantsEric Adler - Chief Medical Officer and Head of ResearchNone - Video NarratorR. Nolan Townsend - CEOConference Call ParticipantsTessa Romero - Senior Biotech AnalystTessa RomeroWelcome, everyone, to the 44th Annual J.P. Morgan Healthcare Conference. My name is Tessa Romero, and I'm one of the Senior Biotech Analysts here at J.P. Morgan. We're pleased to welcome our next presenting company, Lexeo Therapeutics, to ...

PresentationI would now like to turn the conference call over to Louis Tamayo, Chief Financial Officer of Lexeo Therapeutics. Louis, please go ahead.Good morning, and welcome to Lexeo Therapeutics webcast presentation on LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy. As a reminder, this call is being recorded today, January 12.Louis TamayoCFO & Principal Accounting Officer Earlier today, we released interim data from the Lexeo HEROIC-PKP2 Phase I/II clinical trial of LX2020 for t ...

Lexeo Therapeutics Conference Call Summary Company Overview - **Company**: Lexeo Therapeutics (NasdaqGM:LXEO) - **Product**: LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (ACM) Key Industry Insights - **Disease Context**: PKP2-associated ACM affects approximately 60,000 people in the U.S. and is characterized by high risks of cardiac rhythm abnormalities, heart failure, and sudden cardiac death. Over 20% of patients experience sudden cardiac death as their first symptom [doc id='6'][doc id='14']. - **Current Treatment Limitations**: Existing treatments, including ICDs and medications like beta-blockers, do not address the underlying genetic cause of the disease [doc id='7'][doc id='14']. Core Findings from Clinical Trial - **Trial Design**: The Heroic PKP2 phase 1-2 clinical trial is an open-label, single-arm, multicenter trial assessing the safety and efficacy of LX2020 [doc id='15']. - **Participants**: 10 participants have been dosed, with 8 having at least six months of follow-up. The cohort includes patients with advanced disease progression, averaging nine years since diagnosis [doc id='16'][doc id='17']. - **Safety Profile**: LX2020 has been well tolerated with no serious adverse events reported. Some participants experienced elevated liver function tests, which were managed successfully [doc id='18'][doc id='19']. Efficacy Data - **PKP2 Protein Expression**: Significant increases in PKP2 protein expression were observed, with robust vector copy number and mRNA levels indicating effective transduction [doc id='20'][doc id='21']. - **Arrhythmia Burden Reduction**: - **Premature Ventricular Contractions (PVCs)**: A mean improvement of 14% was noted in the high-dose cohort, with stabilization or reduction in PVCs for the majority of participants [doc id='5'][doc id='23']. - **Non-Sustained Ventricular Tachycardia (NSVT)**: A mean improvement of 22% was observed in the high-dose cohort, with reductions in NSVT events indicating a potential decrease in the risk of sustained VT and ICD shocks [doc id='5'][doc id='23']. - **Clinical Measures**: Participants showed stabilization in cardiac function, with no changes in New York Heart Association Class reported [doc id='26']. Future Outlook - **Next Steps**: Enrollment for the Heroic study was completed in Q4 2025, with plans to provide twelve-month follow-up data for all high-dose participants by Q4 2026 [doc id='27']. - **Regulatory Engagement**: Discussions with the FDA regarding future trials and endpoints, particularly focusing on NSVT as a key measure, are anticipated [doc id='37']. Additional Considerations - **Patient Variability**: The trial includes patients with varying disease severity, which may influence the observed efficacy and safety outcomes [doc id='36']. - **Long-term Expectations**: There is optimism regarding the potential for further improvements in arrhythmia burden and cardiac function as data matures [doc id='47']. This summary encapsulates the key points from the Lexeo Therapeutics conference call, highlighting the company's focus on addressing a significant unmet medical need in the treatment of PKP2-associated arrhythmogenic cardiomyopathy through innovative gene therapy.

Core Insights - Lexeo Therapeutics announced preliminary data from the HEROIC-PKP2 Phase I/II clinical trial of LX2020, indicating that the treatment was generally well tolerated and led to significant improvements in PKP2 protein expression and arrhythmia burden in participants [2][3]. Group 1: Clinical Trial Results - The HEROIC-PKP2 trial involved ten participants, with three in the low-dose cohort and seven in the high-dose cohorts [4]. - LX2020 resulted in a mean increase in PKP2 protein expression of 93% in the low-dose cohort and 162% in the high-dose cohorts [8]. - Non-sustained ventricular tachycardia (NSVT) showed a 22% mean improvement in high-dose cohorts, while premature ventricular contractions (PVCs) had a 14% mean improvement [7][13]. - Four out of five participants in high-dose cohorts reported improvement on the Patient Global Impression of Change (PGIC) scale [13]. Group 2: Safety Profile - LX2020 was generally well tolerated, with no clinically significant complement activation reported [8]. - Elevations in liver function tests were observed in five participants at the high dose but resolved without complications [8]. - One serious adverse event of sustained ventricular tachycardia was noted, assessed as possibly treatment-related, but the participant was successfully treated [8]. Group 3: Next Steps and Future Outlook - The company plans to host a webcast to discuss these findings and future developments [9]. - Enrollment for the HEROIC-PKP2 trial was completed in Q4 2025, with 12-month data expected for all high-dose participants in Q4 2026 [13]. - Regulatory engagement is anticipated in 2026 as the company advances the development of LX2020 [13].

Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson’s expertise in cardiovascular therapeutics and circulatory technologies, including Impella™ heart pumps Agreement will enable accelerated development of a preclinical cardiac target using novel, localized routes of viral gene therapy administration NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments ...

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a consensus buy from all eleven analysts covering the stock. While the target price ranges from $12 to $30, the median price target of $19 translates to an upside potential of 79.92%. On December 18, Raymond James initiated coverage on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with a ‘Strong Buy’ rating and a price target of $25, citing solid results fr ...